PHOENIX (March 28, 2017) – Healthcare IT company Topaz Information Services has partnered with iTel Companies Inc., a telehealth company, to offer a seamless integration of telehealth services to its clients. Continue reading
Category Archives: AZBio News
Insys Announces Saeed Motahari to Become President and Chief Executive Officer and Member of the Board of Directors Effective April 17, 2017
On March 27, 2017, Insys Therapeutics, Inc. (NASDAQ:INSY) (“Insys” or “the Company”) announced that, effective April 17, 2017, Saeed Motahari, will become the Company’s President and Chief Executive Officer (“CEO”) and be appointed to the Company’s Board of Directors.Continue reading
Sinema Introduces Fostering Innovation Act
WASHINGTON, D.C. – On March 22, 2017, Congresswoman Kyrsten Sinema (AZ-09) and Congressman Trey Hollingsworth (IN-09) introduced the Fostering Innovation Act, bipartisan legislation to provide commonsense regulatory relief for companies on the cutting edge of scientific and medical research.Continue reading
DEA Schedules Insys Therapeutics’ Syndros (dronabinol oral solution) as Schedule II Drug
On March 23, 2017, Insys Therapeutics, Inc. (NASDAQ:INSY) (“Insys” or the “Company”) announced that the Drug Enforcement Agency (“DEA”) has issued an interim final rule that would result in Syndros™ (dronabinol oral solution) being placed in Schedule II of the Controlled Substances Act. On July 1, 2016, the Food and Drug Administration (“FDA”) approved the New Drug Application for Syndros.Continue reading
HTG Molecular Diagnostics Obtains CE Mark for its HTG EdgeSeq ALKPlus Assay EU
TUCSON, Ariz., March 22, 2017 (GLOBE NEWSWIRE) — HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM), a provider of instruments, reagents, and services for molecular profiling applications, today announced that it has obtained CE marking in the European Union for its HTG EdgeSeq ALKPlus Assay EU.Continue reading
Critical Path Institute launches type 1 diabetes consortium
Critical Path Institute (C-Path) is pleased to announce the launch of the Type 1 Diabetes (T1D) Consortium. Funded by The Leona M. and Harry B. Helmsley Charitable Trust; Janssen Research & Development, LLC; JDRF International; and Sanofi, the T1D Consortium will work to qualify islet autoimmunity antibodies as prognostic biomarkers to be used in the development of therapies for the treatment, and ultimately the prevention, of T1D.
Castle Biosciences’ DecisionDx-Melanoma Test Shown to be a Significant Predictor of Distant Metastasis in Elderly Patients with Melanoma
Additional independent studies presented at the 70th Society of Surgical Oncology Annual Cancer Symposium confirm performance and clinical impact of test.
NASA, ASU collaboration develops new 3-D tissue culture models with immune cells to better mimic human gut infections
The study was led by Cheryl Nickerson, along with co-authors Jennifer Barrila and Jiseon Yang.Continue reading